Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report
Conclusions:
Our data suggest that the pulse pressure value at baseline is a key predictive factor of changes in HbA1c. Co-administration of candesartan with pioglitazone, which have anti-inflammatory (changes in HMW-ADN and PAI-1) effects and protective effects on organs, could be an effective therapeutic strategy for treating hypertensive patients with type 2 diabetes mellitus.Trial registration: UMIN-CTR: UMIN000010142
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Hirofumi SuzukiMasaya SakamotoTakeshi HayashiHiroyuki IuchiKennosuke OhashiTsuyoshi IsakaNoriko SakamotoYosuke KayamaKatsuyoshi TojoMichihiro YoshimuraKazunori Utsunomiya Source Type: research
More News: Actos | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Insulin | Study